Takeda names new president of Europe and Canada business unit

30 March 2017

Takeda Pharmaceutical (TYO: 4502), Japan’s largest drugmaker, said today that Giles Platford will assume the role of president of its Europe and Canada (EUCAN) business unit. In this role he will lead business operations in the region effective April 1, 2017.

Mr Platford, who joined Takeda in 2009, is also a corporate officer and member of Takeda's executive team, reporting to Christophe Weber, president and chief executive Officer of Takeda.

"EUCAN has been a high performing region in the last few years, and I am fully confident that Giles, with his solid business ability and understanding of Takeda values, is the ideal choice to lead this business unit," said Mr Weber, adding: "His proven track record with the company in senior leadership roles across diverse geographies and cultures will no doubt bring a unique perspective and value to all facets of Takeda business in Europe and Canada."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK